Physician profile
Anny Sosebee
NPI 1164916581
$2,738.06
in general payments reported to CMS, 2019-2025
35 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.04 · 2022: $50.97 · 2023: $640 · 2024: $912 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.76 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.35 | 2023-2025 | |
| Corcept Therapeutics | $433.21 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $188.92 | 2023-2025 | Farxiga, Airsupra |
| Braeburn INC. | $185.42 | 2024-2025 | Brixadi |
| Exact Sciences Corporation | $143.12 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $137.57 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $129.39 | 2024-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $109.06 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $94.60 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.14 | 2024-2025 | Rexulti |
| Pfizer INC. | $68.32 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.70 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $64.54 | 2024-2025 | Trelegy Ellipta |
| Sobi, INC | $49.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.76 | 2024 | Ofev, Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.61 | 2023-2024 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.04 | 2025 | Xifaxan |
| Abbott Laboratories | $41.67 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $38.40 | 2024 | Yupelri |
| Indivior INC. | $35.18 | 2024-2025 | Sublocade |
| Vertex Pharmaceuticals Incorporated | $34.99 | 2025 | |
| Alkermes, INC. | $27.58 | 2025 | Vivitrol |
| Merck Sharp & Dohme LLC | $27.29 | 2021-2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Gilead Sciences, INC. | $26.00 | 2023 | |
| Medtronic, INC. | $19.91 | 2024 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $19.58 | 2022 | |
| Seqirus USA INC | $18.11 | 2025 | Flucelvax |
| Lundbeck LLC | $18.08 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $17.68 | 2021 | |
| Axsome Therapeutics, INC. | $15.83 | 2025 | Auvelity |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2023 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $13.84 | 2024 | Unithroid |
| Amgen INC. | $13.57 | 2024 | Repatha, Otezla |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anny Sosebee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.